POSEIDON: Two ICIs Plus Chemo Up Survival in mNSCLC

Patiehts with stage IV non–small cell lung cancer have better outcomes when tremelimumab is added to durvalumab and chemo, a phase 3 trial shows, but questions remain over the role of anti-CTLA-4 agents. Medscape Medical News
Read More

Related Posts